Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk

Massimo Volpe, Allegra Battistoni, Giovanna Gallo, Roberta Coluccia, Raffaele De Caterina

Research output: Contribution to journalArticle

Abstract

While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well established, aspirin in primary prevention is not systematically recommended because the absolute CV event reduction is similar to the absolute excess in major bleedings. Recently, emerging evidence suggests the possibility that the assumption of aspirin, may also be effective in the prevention of cancer. By adding to the CV prevention benefits the potential beneficial effect of aspirin in reducing the incidence of mortality and cancer could tip the balance between risks and benefits of aspirin therapy in the primary prevention in favour of the latter and broaden the indication for treatment with in populations at average risk. While prospective and randomized study are currently investigating the effect of aspirin in prevention of both cancer and CVD, clinical efforts at the individual level to promote the use of aspirin in global (or total) primary prevention could be already based on a balanced evaluation of the benefit/risk ratio.

Original languageEnglish
Pages (from-to)331-339
Number of pages9
JournalHigh Blood Pressure and Cardiovascular Prevention
Volume24
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Keywords

  • Aspirin
  • Cancer
  • Cardiovascular risk
  • Primary prevention

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk'. Together they form a unique fingerprint.

  • Cite this